Dual-center retrospective study on the efficacy and safety of neoadjuvant therapy in the patients with resectable pancreatic cancer

Dual-center retrospective study on the efficacy and safety of neoadjuvant therapy in the patients with resectable pancreatic cancer - Retrospective study on the efficacy and safety of neoadjuvant therapy in the patients with resectable pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000052876

Enrollment

550

Registered

2023-12-01

Start date

2023-10-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. histologically confirmed as pancreatic adenocarcinoma 2. diagnosis of resectable pancreatic cancer according to NCCN guideline (Ver.2. 2021)

Exclusion criteria

Exclusion criteria: 1. diagnosis of borderline or unresectable pancreatic cancer according to NCCN guideline (Ver.2. 2021) 2. conversion surgery in the patients with unresectable pancreatic cancer

Design outcomes

Primary

Measure	Time frame
Comparison of overall survival between upfront surgery and neoadjuvant therapy in the patients with resectable pancreatic cancer	—

Secondary

Measure	Time frame
1. detection of prognostic factor in the patients with resectable pancreatic cancer 2. comparison of recurrence free survival between upfront surgery and neoadjuvant therapy 3. comparison of surgical outcome between upfront surgery and neoadjuvant therapy 4. comparison of morbidity and induction of the adjuvant therapy between upfront surgery and neoadjuvant therapy 5. detection of the unresectable factor in the patients received neoadjuvanvt therapy with resectable pancreatic cancer	—

Measure

Time frame

1. detection of prognostic factor in the patients with resectable pancreatic cancer 2. comparison of recurrence free survival between upfront surgery and neoadjuvant therapy 3. comparison of surgical outcome between upfront surgery and neoadjuvant therapy 4. comparison of morbidity and induction of the adjuvant therapy between upfront surgery and neoadjuvant therapy 5. detection of the unresectable factor in the patients received neoadjuvanvt therapy with resectable pancreatic cancer

—

Countries

Japan

Contacts

Public ContactAtsushi Shimizu

School of Medicine, Wakayama Medical School Second Department of Surgery

atsus28@wakayama-med.ac.jp073-441-0613

Outcome results